Trodelvy notch­es a win in most com­mon form of breast can­cer

Fol­low­ing a promise last year to go “big and fast in breast can­cer,” Gilead has se­cured a win for Trodelvy in the most com­mon form …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.